DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Commercial Interests at ASCO 2017 - A 1stOncology Insights Report" report to their offering.
The Commercial Interests at ASCO 2017 report is a must have companion tool for reviewing the direction of commercial drug development emerging from the American Society of Clinical Oncology (ASCO) Annual Meeting 2017. Break through the mountain of close 5,000 abstracts presented at ASCO 2017 with a focused entry to reveal the identity and position of more than 470 commercial drugs at the core of the oncology landscape.
These identified drugs range from early development to marketed and in this report are analyzed across 14 hot areas in oncology, including sections such as exciting Startups, Immune checkpoint drugs, Epigenetic therapies, DNA Damage response drugs and many more. Each hot area analyzed reveals the core R&D focus of commercial actors, the targeting landscape (with many cases of unique targets not currently under development by any other company), drugs with biomarkers, drugs in combination therapy development and much more.
To further illuminate the reader, this report also includes more than 1,000 references detailing the latest positive and negative pipeline development from throughout 2016 to present for circa two hundred top cancer drugs. This provides comprehensive insight to current developments such as successful clinical trials, trials with missed primary endpoints, new or terminated partnerships, M&A and much more.
The ASCO Annual Meeting is one of the few truly key events on a global scale that tell us the direction of commercial drug development in oncology. This report is a must read for anyone with an interest in oncology who wants to save time and effort and more successfully analyze the direction emerging from this meeting.
Key Topics Covered:
1 Executive Summary
2 About 1stOncology Insights
3 Table of Contents
4 Major Recent Developments on Cancer Drugs at ASCO from 2016 to Present
5 Overview of Cancer Drugs at ASCO 2017
6 ASCO 2017 by Startups
7 ASCO 2017 by Fierce 15 Companies
8 ASCO 2017 by Orphan Drugs
9 ASCO 2017 by Breakthrough Therapies
10 ASCO 2017 by Cancer Vaccines
11 ASCO 2017 by CAR/TCR Therapies
12 ASCO 2017 by Immune Checkpoint Drugs
14 ASCO 2017 by DNA Damage Response Drugs
15 ASCO 2017 by Protein Kinase Inhibitors
16 ASCO 2017 by Antibody Drugs
17 ASCO 2017 by Peptide Drugs
18 ASCO 2017 by Nucleic Acid Therapies
19 ASCO 2017 by Conjugated Drugs
20 Disclaimer
21 Drug Index
22 Drug Innovator Index
For more information about this report visit https://www.researchandmarkets.com/research/5zsnbs/commercial
